Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03783442
Title A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors BeiGene
Indications

esophagus squamous cell carcinoma

Therapies

Cisplatin

Paclitaxel

Tislelizumab

Oxaliplatin

Fluorouracil

Capecitabine

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.